Physician profile
Susan Ross
NPI 1881648152
$3,917.56
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,857 · 2020: $667 · 2021: $38.52 · 2022: $52.10 · 2023: $168 · 2024: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $303.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $770.61 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $310.75 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $284.80 | 2019-2020 | |
| Astellas Pharma US INC | $264.37 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $245.07 | 2019-2020 | |
| Genzyme Corporation | $167.20 | 2019-2020 | |
| Amgen INC. | $163.57 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $141.81 | 2019-2023 | |
| Seagen INC. | $138.24 | 2019 | |
| Janssen Biotech, INC. | $132.42 | 2019-2020 | |
| Celgene Corporation | $105.63 | 2019 | |
| Novo Nordisk INC | $102.17 | 2023-2024 | Rybelsus, Ozempic |
| Horizon Therapeutics Plc | $85.97 | 2019 | |
| Abbvie INC. | $81.42 | 2019-2023 | Venclexta |
| Abbott Laboratories | $60.81 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.